🎉 M&A multiples are live!
Check it out!

Sagimet Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sagimet Biosciences and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

Sagimet Biosciences Overview

About Sagimet Biosciences

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.


Founded

2006

HQ

United States of America
Employees

14

Website

sagimet.com

Financials

LTM Revenue n/a

LTM EBITDA -$83.7M

EV

-$74.5M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Sagimet Biosciences Financials

Sagimet Biosciences has a last 12-month revenue of n/a and a last 12-month EBITDA of -$83.7M.

In the most recent fiscal year, Sagimet Biosciences achieved revenue of n/a and an EBITDA of -$54.5M.

Sagimet Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Sagimet Biosciences valuation multiples based on analyst estimates

Sagimet Biosciences P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $2.0M n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$30.7M -$54.5M XXX XXX XXX
EBITDA Margin -1537% -Infinity% XXX XXX XXX
Net Profit -$30.5M -$27.9M XXX XXX XXX
Net Margin -1525% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Sagimet Biosciences Stock Performance

As of April 15, 2025, Sagimet Biosciences's stock price is $2.

Sagimet Biosciences has current market cap of $76.6M, and EV of -$74.5M.

See Sagimet Biosciences trading valuation data

Sagimet Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$74.5M $76.6M XXX XXX XXX XXX $-2.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Sagimet Biosciences Valuation Multiples

As of April 15, 2025, Sagimet Biosciences has market cap of $76.6M and EV of -$74.5M.

Sagimet Biosciences's trades at n/a LTM EV/Revenue multiple, and 0.9x LTM EBITDA.

Analysts estimate Sagimet Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Sagimet Biosciences and 10K+ public comps

Sagimet Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$74.5M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 1.4x XXX XXX XXX
P/E -1.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sagimet Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Sagimet Biosciences Valuation Multiples

Sagimet Biosciences's NTM/LTM revenue growth is n/a

Sagimet Biosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.9M for the same period.

Over next 12 months, Sagimet Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Sagimet Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Sagimet Biosciences and other 10K+ public comps

Sagimet Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -100% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 77% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $3.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Sagimet Biosciences Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Sagimet Biosciences M&A and Investment Activity

Sagimet Biosciences acquired  XXX companies to date.

Last acquisition by Sagimet Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Sagimet Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Sagimet Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Sagimet Biosciences

When was Sagimet Biosciences founded? Sagimet Biosciences was founded in 2006.
Where is Sagimet Biosciences headquartered? Sagimet Biosciences is headquartered in United States of America.
How many employees does Sagimet Biosciences have? As of today, Sagimet Biosciences has 14 employees.
Who is the CEO of Sagimet Biosciences? Sagimet Biosciences's CEO is Mr. David Happel.
Is Sagimet Biosciences publicy listed? Yes, Sagimet Biosciences is a public company listed on NAS.
What is the stock symbol of Sagimet Biosciences? Sagimet Biosciences trades under SGMT ticker.
When did Sagimet Biosciences go public? Sagimet Biosciences went public in 2023.
Who are competitors of Sagimet Biosciences? Similar companies to Sagimet Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Sagimet Biosciences? Sagimet Biosciences's current market cap is $76.6M
What is the current EBITDA of Sagimet Biosciences? Sagimet Biosciences's last 12-month EBITDA is -$83.7M.
What is the current EV/EBITDA multiple of Sagimet Biosciences? Current EBITDA multiple of Sagimet Biosciences is 0.9x.
Is Sagimet Biosciences profitable? Yes, Sagimet Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.